Publicaciones en colaboración con investigadores/as de Université de Tunis El Manar (9)

2024

  1. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

    Journal of Neurology, Vol. 271, Núm. 9, pp. 5813-5824

  2. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

    Journal of medical economics, Vol. 27, Núm. 1, pp. 109-125

  3. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study

    Journal of Neurology, Neurosurgery and Psychiatry

2023

  1. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713

  2. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  3. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

2022

  1. Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 1, pp. 23-30

  2. It is time to define an organizational model for the prevention and management of infections along the surgical pathway: a worldwide cross-sectional survey

    World Journal of Emergency Surgery, Vol. 17, Núm. 1

  3. The ChoCO-W prospective observational global study: Does COVID-19 increase gangrenous cholecystitis?

    World Journal of Emergency Surgery, Vol. 17, Núm. 1